Search Result

Results for "

anti-tuberculosis activities

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (6) Bacterial (41) DNA/RNA Synthesis (1) Fungal (5) Parasite (1) Potassium Channel (1) Ser/Thr Protease (2) STAT (3) Thrombopoietin Receptor (2) VEGFR (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Infection (43) Inflammation/Immunology (11) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0276

Ethionamide 1 Publications Verification 2-Ethylthioisonicotinamide	Bacterial Antibiotic	Infection
Ethionamide (2-ethylthioisonicotinamide) is a second-line anti-tuberculosis antibiotic with antibacterial effect and oral activity .

HY-148478

MMV688845 (R)-GSK1729177A	DNA/RNA Synthesis	Infection
MMV688845 is a nontuberculous mycobacteria (NTM) RNA polymerase inhibitor with bactericidal activity against Mycobacterium abscessus and anti-tuberculosis efficacy .

HY-12485

TBA-354	Bacterial Antibiotic	Infection
TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains.

HY-126597

Chaetoglobosin C	Bacterial	Infection
Chaetoglobosin C (Compound 4) is a anthraquinone-chromone compound derived from the fungus Chaetomium globosum KMITL-N0802. Chaetoglobosin C has anti-tuberculosis activity .

HY-151956

Mtb-cyt-bd oxidase-IN-7	Bacterial	Infection
Mtb-cyt-bd oxidase-IN-7 is a cytochrome bd terminal oxidase (Cyt-bd) inhibitor with a K_d value of 4.17 μM. Mtb-cyt-bd oxidase-IN-7 shows anti-tuberculosis activities .

HY-W716673

Ftivazide Phthivazide	Bacterial	Infection
Ftivazide has anti-tuberculosis activity .

HY-146158

WX-081	Bacterial Potassium Channel Antibiotic	Infection
WX-081, an anti-tuberculosis agent, displays excellent anti-mycobacterial activity against M. tuberculosis H37Rv and low cytotoxicity. WX-081 exhibits potent activity with MIC50s of 0.083 and 0.11 μg/mL for agent susceptible tuberculosis (DS-TB) and multidrug resistant tuberculosis (MDR-TB) strains. WX-081 also inhibits hERG channel with the IC50 of 1.89 μM.

HY-117126

BTZ-N3	Bacterial	Infection
BTZ-N3 is a potent reversible and noncovalent inhibitor of decaprenylphosphoryl-β-d-ribose 2′ oxidase (DprE1) that shows anti-tuberculosis activity .

HY-146057

Antituberculosis agent-2	Bacterial	Infection
Antituberculosis agent-2 (Compound 8d) is an antituberculosis agent against agent-sensitive and multidrug-resistant tuberculosis. Antituberculosis agent-2 shows anti-tuberculosis activity with MIC values of 0.454, 1.757 and 1.644 μg/mL against M. tuberculosis H₃₇R_v, 13946 and 14862, respectively. Antituberculosis agent-2 displays favorable mouse and human microsomal stability, low cytotoxicity, and acceptable oral bioavailability .

HY-121463

Rubrosulphin	Bacterial	Infection
Rubrosulphin is a fungal metabolite, which can be isolated from Aspergillus sp.. Rubrosulphin exhibits slight anti-tuberculosis activity, inhibits Mycobacterium bovis and M. smegmatis with MIC >200 µg/mL .

HY-162028

GaMF1.39	Bacterial	Infection
GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors .

HY-162094

Antitubercular agent-44	Bacterial	Infection
Antitubercular agent-44 (compound 21b) has anti-tuberculosis (H37Rv MIC = 0.06 μM). Antitubercular agent-44 has oral activity .

HY-114604

Propioxatin B	Others	Others
Propioxatin B is a tricyclic sesquiterpenoid compound isolated from the root of vetiver grass. It has anti-tuberculosis activity and inhibitory effects on a variety of drug-resistant mutants of Mycobacterium tuberculosis. In computer simulation docking studies, it showed binding affinity with bacterial DNA gyrase and has a certain safety in vivo.

HY-162527

Antibacterial agent 216	Bacterial	Infection
Antibacterial agent 216 (Compound 2a) is an antibacterial agent that exhibits significant bactericidal effects when combined with INH and RIF. Antibacterial agent 216 has demonstrated remarkable in vitro anti-tuberculosis activity against Mtb H37Rv and MDR clinical isolates and can be used for tuberculosis research .

HY-150967

MmpL3-IN-1	Bacterial	Infection
MmpL3-IN-1 (compound 32) is a potent Mycobacterial membrane protein large 3 (MmpL3) inhibitor. MmpL3-IN-1 has anti-tuberculosis activity with the MIC<0.016 μg/mL in M. tuberculosis and can be used in studies of drug-resistant tuberculosis .

HY-117145

Thiophene-2	Bacterial	Infection
Thiophene-2 (TP2) is a specific polyketide synthase 13 (Pks13) inhibitor. Thiophene-2 inhibits mycolic acid biosynthesis and rapidly leads to mycobacterial cell death. Thiophene-2 is active against *Mycobacterium tuberculosis* with a MIC value of 1 μM, and has potent anti-tuberculosis activity .

HY-N1887

4-Allylcatechol 1 Publications Verification Hydroxychavicol; 4-Allylpyrocatechol	Bacterial	Infection Cardiovascular Disease
4-Allylcatechol (4-Allylpyrocatechol) is a xylan isolated from the root of Piper taiwanense. 4-Allylcatechol has a strong inhibitory activity against collagen-induced platelet aggregation (IC₅₀=5.3 μM). In addition, 4-Allylcatechol has anti-tuberculosis activity against Mycobacterium tuberculosis H37Rv (MIC=27.6 μg/mL) .

HY-159565

VEGFR-2/InhA-IN-1	Bacterial VEGFR	Infection
VEGFR-2/InhA-IN-1 is a pyrazole-based dual inhibitor of InhA-VEGFR with anti-tuberculosis and anti-angiogenic activities. VEGFR-2/InhA-IN-1 has good antibacterial activity against Mycobacterium tuberculosis H37Rv strain (MIC=6.25 μg/mL) and significantly inhibits VEGFR-2 (IC₅₀=15.27 nM) .

HY-158380

UH-NIP-16	Bacterial	Infection
UH-NIP-16 exhibits antimicrobial activity against Mycobacterium tuberculosis, with MIC₅₀ of 1.86 and 3.05 μM, for pathogenic mycobacterial strains H37Rv and CDC1551. UH-NIP-16 synergizes with Streptomycin (HY-B1906), Isoniazid (HY-B0329), Ethambutol (HY-B0535) and Bedaquiline (HY-14881), potentiates their anti-tuberculosis activities .

HY-162508

KSK-104	Bacterial	Infection
KSK-104 has potent antibacterial activity against Mycobacterium tuberculosis (MIC=0.78 μM). The role of KSK-104 is mainly involved in the synthesis and recovery pathways of pyridoxal 5'-phosphate (PLP), PLP-dependent enzymes and oxidative stress networks. KSK-104, as a candidate molecule for novel anti-tuberculosis drugs, can be used to develop research against drug-resistant mycobacterium tuberculosis .

HY-162521

Antibacterial agent 215	Bacterial Fungal	Infection
Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonic anhydrase (CA), with K_i of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .

HY-145286

IMPDH2-IN-2	Bacterial	Infection Cancer
IMPDH2-IN-2 is a potent inhibitor of inosine 5’-monophosphate dehydrogenase (IMPDH) with a K_i,app value of 14 μM, respectively. IMPDH2-IN-2 displays moderate antibacterial activity (MIC = 6.3 and 11 μM in minimal GAST/Fe and rich 7H9/ADC/Tween media, respectively). IMPDH2-IN-2 is a potential anti-tuberculosis agent .

HY-152136

Antituberculosis agent-6	Bacterial Fungal	Infection
Antituberculosis agent-6 (compound 9g) is a potent antimycobacterial agent. Antituberculosis agent-6 shows significant activity against M. tuberculosis, with a MIC of 3.49 μM. Antituberculosis agent-6 also shows good antifungal activity against A. niger, with a MIC of 62.50 μM. Antituberculosis agent-6 shows high GI absorption .

HY-151205

Antituberculosis agent-3	Bacterial	Infection Inflammation/Immunology
Antituberculosis agent-3 (Compound 2) is an antituberculosis agent. Antituberculosis agent-3 shows anti-mycobacterial activity, and can inhibit M. tuberculosis H37Rv strain growth (MIC=12.5 μg/mL) .

HY-151598

Pks13-TE inhibitor 2	Bacterial	Infection
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-151599

Pks13-TE inhibitor 3	Bacterial	Infection
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-N1103

Vasicine Peganine	Bacterial	Inflammation/Immunology
Vasicine (peganine) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity .

HY-N1103A

Vasicine hydrochloride Peganine hydrochloride	Bacterial	Infection Inflammation/Immunology
Vasicine hydrochloride (peganine hydrochloride) is a quinazoline alkaloid isolated from Justicia adhatoda. Vasicine (peganine) possesses anti- tuberculosis activity .

HY-152137

Antituberculosis agent-7	Bacterial Fungal Antibiotic	Infection Inflammation/Immunology
Antituberculosis agent-7, an oxetanyl-quinoline derivative, has shown good antibacterial activity against P. mirabilis with a MIC of 31.25 μM. Antituberculosis agent-7 shows good antifungal activity against A. niger with a MIC of 62.5 μM. Antituberculosis agent-7 shows excellent antimycobacterial activity with MIC 3.41 μM for M. tuberculosis H37Rv .

HY-163486

Antituberculosis agent-10	Bacterial	Infection
Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against *Mycobacterium tuberculosis* (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .

HY-151514

Antituberculosis agent-5	Bacterial	Infection
Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC₅₀ value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .

HY-113834

(R,R)-Ethambutol	Bacterial	Infection
(R,R)-Ethambutol is an antituberculosis compound with tuberculosis inhibitory activity. (R,R)-Ethambutol is often used in combination with other antituberculosis compounds to enhance the efficacy. (R,R)-Ethambutol can also be used to inhibit Mycobacterium avium complex infection and Mycobacterium kansasii infection .

HY-152138

Antituberculosis agent-8	Bacterial Fungal	Infection
Antituberculosis agent-8 (Compound 9i) is an antitubercular agent with an MIC of 3.53 μM (1.6 μg/mL) against *M. tuberculosis H37Rv. Antituberculosis* agent-8 also shows good antifungal activity against A. niger with an MIC of 62.50 μM .

HY-139863

Antibacterial agent 62	Bacterial	Infection
Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.

HY-155067

Antitubercular agent-38	Bacterial	Infection
Antitubercular agent-38 is an orally active Benzothiazinones (BTZs) derivate, with potent antituberculosis activity. Antitubercular agent-38 exhibits low cardiac toxicity, low cell cytotoxicity .

HY-119166

3,5,4'-Tribromosalicylanilide	Others	Others
3,5,4'-Tribromosalicylanilide is a compound with antituberculosis and anti-Mycobacterium abscessus activities, which was found to inhibit the growth of Mycobacterium tuberculosis and Mycobacterium abscessus and affect gene expression by computational compound repositioning approach.

HY-134940

Quabodepistat OPC-167832	Bacterial	Infection Inflammation/Immunology
Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with an IC₅₀ of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis .

HY-169108

DprE1-IN-11	Bacterial	Infection
DprE1-IN-11 (compound 3) is an orally active DprE1 inhibitor with antituberculosis activity against MTB H37Rv and MDR-MTB strains (MIC <0.029-0.095 μM) .

HY-N13197

5,6-Dihydro-6-methyl-2H-pyran-2-one	Antibiotic Bacterial Fungal Parasite	Infection Inflammation/Immunology Cancer
5,6-Dihydro-6-methyl-2H-pyran-2-one is a heterocyclic compound with antitumor, antifungal, antimicrobial, anti-inflammatory, antistress, antibiotic, antituberculosis, antiparasitic, antiviral activities .

HY-116943

MTC420	Bacterial	Infection
MTC420 (compound 42a) is a heterocyclic quinolone compound that targets the respiratory chain of Mycobacterium tuberculosis and exhibits antituberculosis activity (Rep Mtb: IC₅₀=525 nM, Wayne Mtb: IC₅₀=76 nM, MDR Mtb: IC₅₀=140 nM) .

HY-129819

(Rac)-DNDI-8219	Bacterial	Infection
(Rac)-DNDI-8219 is an antituberculosis compound with potent anti-leishmanial activity. (Rac)-DNDI-8219 demonstrated superior efficacy in the Leishmania donovani mouse model. (Rac)-DNDI-8219 showed promising activity in the Leishmania infantum hamster model. (Rac)-DNDI-8219 candidate compound R-6 provided excellent oral efficacy in the same hamster model .

HY-B0276A

Ethionamide hydrochloride 2-Ethylthioisonicotinamide hydrochloride	Others	Infection
Ethionamide hydrochloride (2-Ethylthioisonicotinamide hydrochloride) is an antituberculosis drug with mycobacterial activity. Ethionamide hydrochloride interferes with the bacterial cell wall synthesis process by inhibiting the synthesis of fatty acids in the bacterial cell wall. Ethionamide hydrochloride may have bacteriostatic or bactericidal effects, depending on the concentration of the drug at the site of infection and the susceptibility of the associated microorganisms. Ethionamide hydrochloride combines with NAD+ to form an adduct, thereby exerting its antibacterial effect .

HY-155558

MptpB-IN-2	Antibiotic	Infection
MptpB-IN-2 (compound 20) is a selective mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with IC₅₀s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis activity with a MIC of 64.9 μM for Mtb H37Rv .

HY-14743B

Golotimod hydrochloride SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-14743

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-14743A

Golotimod TFA SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-D0837

Imidazole 2 Publications Verification Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene	Ser/Thr Protease Thrombopoietin Receptor	Neurological Disease Inflammation/Immunology
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-D0837R

Imidazole (Standard)	Ser/Thr Protease Thrombopoietin Receptor	Neurological Disease Inflammation/Immunology
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Cat. No.	Product Name

HY-L142

Anti-tuberculosis Compound Library

103 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 103 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Type

HY-D0837

Imidazole

2 Publications Verification

Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

Cell Assay Reagents

Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-D0837R

Imidazole (Standard)

Cell Assay Reagents

Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Cat. No.	Product Name	Target	Research Area

HY-14743

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-125576

Griselimycin	Peptides	Others
Griselimycin is a compound with antituberculosis activity that exhibits good in vitro and in vivo activity against sensitive and resistant Mycobacterium tuberculosis, and its cyclohexyl derivative has high transformative potential.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks